CP 690,550-d3详情 评价(0) 货号:ajcx22138 CAS:N/A 别名: 分子式:C16H17D3N6O.C6H8O7 分子量:507.5 纯度:>98% 溶解度:DMSO: soluble,Water: soluble 储存:Store at -20°C 库存:现货 Background CP 690,550-d3is intended for use as an internal standard for the quantification of CP 690,...
2010年3月30---31两日,来自辉瑞公司美国总部的亚洲临床研究质量保证负责人Helen Q MD、RAIN MD等对正在风湿免疫科进行的国际多中心注册实验——“CP690,550治疗中重度类风湿关节炎的安全性和有效性3期临床试验”进行了质量检查。做为中国入组第一,全球入组第三的中心注册实验,试验负责人刘毅主任积极组织科室配合...
中国临床试验数据库提供关于托法替布治疗类风湿关节炎的长期、开放随访研究的登记号CTR20132936,药物名称托法替尼(CP-690,550),以及适应症和试验专业题目等其他临床试验数据,更多关于托法替布治疗类风湿关节炎的长期、开放随访研究的资料信息就在戊戌数据中国临床试验数据
BackgroundPsoriasis is a chronic, inflammatory skin disease with a significant impact on health–related quality of life (HRQoL). Tofacitinib (CP-690,550) is a novel, oral Janus kinase inhibitor that is being investigated as a targeted immunomodulator.ObjectiveThis Phase 2b study assessed three tof...
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized ... Y Tanaka,SH Zwillich - 《Japanese Journal of Rheumatology》 被引量: 2发表: 2016年 AB0517THREE-YEAR SAFETY OF TOFACITINIB IN PATIENTS WITH ...
中文别名 3-((3R,4R)-4-甲基-3-(甲基(7H-吡咯并[2,3-d]嘧啶-4-基)氨基)哌啶-1-基)-3-氧代丙腈;CP 690550;CP-690550;3-((3R,4R)-4-甲基-3-(甲基(7H-吡咯并(2,3-d)嘧啶-4-基)氨基)哌啶-1-基)-3-氧代丙腈;托法替布 CAS RN 477600-75-2 EINECS号 分子式 C16H20N6O 分子量 ...
CP690550 Free after splitting 中文名: CP690550 拆分后游离的 中文别名: CP690550 拆分后游离的 CBNumber: CB310876315 分子式: 分子量: 0 MOL File: Mol file 化学性质安全信息用途供应商1 CP690550 拆分后游离的化学性质 安全信息 CP690550 拆分后游离的性质、用途与生产工艺 ...
Jaquinus, Xeljanz, tofacitinib (CP-690,550, CP-690550, tasocitinib) - BioCentury Product Profiles for the biopharma industry
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) in... OBJECTIVES: To determine the efficacy of CP-690,550 in improving pain, function and health status in patients with moderate to severe ...
The Jak inhibitor CP-690,550 inhibits alloreactivity and is currently being investigated for prevention of allograft rejection after transplantation. In this study, we examined the effect of CP-690,550 on IL-2-mediated Jak/STAT5 phosphorylation by CD4+CD25brightFoxP3+CD127−/low T cells (...